drugset / Trial / NCT00491855
Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research is to learn acceptable dosages of paclitaxel, oxaliplatin, and Avastin (bevacizumab) that can be given in combination to patients with advanced peritoneal carcinomatosis. The safety of this drug combination will also be studied.
Timeline
- Start
- 2007-06
- Primary completion
- 2012-12
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 2.5 mg/kg | Intravenous |
| Subject | Oxaliplatin | Small molecule | 25 mg/m2 | Other |
| Subject | Paclitaxel | Small molecule | 30 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 110 mg/m2 | Intravenous |